NCT02046928

Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)

A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Ångstrom Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).

Detailed description

In patients diagnosed with CLL or SLL, study medication will be injected subcutaneously two times a day in an outpatient setting for up to 6 cycles (28 days = 1 cycle) prior to the primary endpoint assessment.

Conditions

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma
• CLL
• SLL

Interventions

Type	Name	Description
DRUG	A6	A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).

Timeline

• Start date: 2014-02-01
• Primary completion: 2015-11-01
• Completion: 2016-03-01
• First posted: 2014-01-28
• Last updated: 2016-07-13

Locations

1 site across 1 country: United States